MMS

MMS MMS is an innovative, data-focused CRO that supports the pharmaceutical, biotech, and medical device industries with a proven, scientific approach.

MMS Holdings (MMS) is an innovative, data-focused CRO that supports the pharmaceutical, biotech, and medical device industries with a proven, scientific approach to complex trial data and regulatory submission challenges. Strong industry experience, technology-enabled services, and a data-driven approach to drug development make MMS a valuable CRO partner, creating compelling submissions that meet rigorous regulatory standards. With a global footprint across four continents, MMS maintains a 97 percent customer satisfaction rating, and the company has been recognized as a leading CRO in Global Health & Pharma’s international awards programs for three consecutive years.

Next week, MMS will be speaking on data interpretation in early oncology. The session will address how sponsors can stre...
03/20/2026

Next week, MMS will be speaking on data interpretation in early oncology. The session will address how sponsors can strengthen evidentiary confidence through smarter data strategy, clearer endpoint alignment, and meaningful interim interpretation.

Moderated by Ben Dudley, CCO at MMS, thought leaders on this panel include:
- Andrew Krivoshik, MD, PhD, PE, Chief Medical Officer at PAQ Therapeutics
- Mark Stewart, PhD, Vice President of Science Policy at Friends of Cancer Research
- Aiden Flynn, PhD, Senior Vice President, Strategic Statistical Services at MMS

Strong oncology programs are those that are built on how data is framed, challenged, and communicated to regulators and stakeholders at every stage.

Register now to gain practical insights: https://hubs.li/Q047H9xK0

MMS is growing and we are hiring across several key roles! We are currently looking for experienced Project Managers, Me...
03/19/2026

MMS is growing and we are hiring across several key roles! We are currently looking for experienced Project Managers, Medical Writers, and Statistical Programmers to join our global team supporting complex clinical development programs.

These roles are open globally, and many positions offer remote flexibility, allowing talented professionals to contribute from wherever they work best.

At MMS, you will collaborate with experts in regulatory affairs, biometrics, safety, and clinical data to help sponsors move therapies forward. If you are ready to work on meaningful programs with a team that values collaboration, expertise, and impact, we would love to hear from you.

Explore open opportunities with MMS now: https://hubs.li/Q047mzlF0

03/18/2026

Twenty years ago MMS was founded on a simple belief, that data is the most valuable asset for sponsors, and quality should anchor every decision.

Reflecting on this milestone, our Founder & CEO Dr. Uma Sharma highlights a journey shaped by people, scientific rigor, and trusted partnerships. What began as a focused vision has grown into a global team supporting complex programs, expedited pathways, and high‑stakes submissions worldwide.

As MMS enters its 20th year of service, the commitment to advancing science and supporting better therapies for patients remains stronger than ever.

Clinical data drives every development decision, and that’s why sponsor like this large pharma partner with MMS for clin...
03/17/2026

Clinical data drives every development decision, and that’s why sponsor like this large pharma partner with MMS for clinical data management that delivers speed, visibility, and control across complex studies.

Here is what that looks like in practice.
✅ Smart teams building and managing studies in Rave, Zelta, and Medrio
✅ Deployment of modern technologies including eCOA, eClinRO, ePRO, eDiary, and eConsent
✅ Deep therapeutic expertise across global programs
✅ Proven processes that help studies launch faster and maintain clean, reliable data
✅ Near real-time data visibility through Datacise visual analytics
✅ A single point of contact that simplifies communication and strengthens continuity

Gain clean, reproducible, fit for analysis data by partnering with MMS for Clinical Data Management solutions! See more details at https://hubs.li/Q0473pxh0.

A special day at ACDM Berlin, with Lucy Sutton stepping in to deliver Doreen Van Huyssteen’s session, “Risk‑Based Data M...
03/16/2026

A special day at ACDM Berlin, with Lucy Sutton stepping in to deliver Doreen Van Huyssteen’s session, “Risk‑Based Data Management Success Factors and Associated Risks,” following travel disruption.

Lucy’s willingness to step up at short notice is a great example of exceptional commitment and professionalism. The session explored how RBQM continues to shift data oversight from uniform review models to more targeted, risk‑informed approaches, and what organisations must consider to implement it effectively in practice.

If you’d like to speak with Lucy following the session, please make your way over to Booth #28.

ACDM 2026 in Berlin starts today, and if you are attending this week, here are three ways to connect with MMS: 1️⃣ VISIT...
03/16/2026

ACDM 2026 in Berlin starts today, and if you are attending this week, here are three ways to connect with MMS:

1️⃣ VISIT: Stop by our booth to meet the MMS team and see how Datacise helps sponsors strengthen clinical data oversight with real-time visual analytics. Request a meeting: https://hubs.li/Q046TpSQ0

2️⃣ LISTEN: Two thoughts leaders from MMS were asked to present on-site. Doreen Van Huyssteen will present Risk Based Data Management Success Factors and Associated Risks, exploring how RBQM is shifting data oversight toward targeted, risk informed review. Minya Engelbrecht will present Clinical Data Management Soft Skill Utilization Translating Neuro-Linguistic Programming into Higher Customer Satisfaction, examining how communication and behavioral insight shape stronger sponsor relationships. View the agenda: https://hubs.li/Q046TtqB0

3️⃣ EXPERIENCE: Datacise has been named a Finalist for Innovation in the Management of Clinical Data at the 2026 ACDM Awards, recognizing how modern analytics can support clearer oversight and smarter decision making. Learn why and ask for a demo: https://hubs.li/Q046TrlZ0

If you are in Berlin this week, we would love to connect!

PHUSE US Connect is happening this month! MMS experts will be an integral part of the conversation, as the team is prese...
03/13/2026

PHUSE US Connect is happening this month! MMS experts will be an integral part of the conversation, as the team is presenting three sessions focused on strengthening collaboration and expanding how data science supports clinical development.

The sessions include:

✅ Building Cross-Functional Regulatory and Programming Alignment for Successful Submissions

✅ Estimand-Aligned Multiple Imputation Strategies in CNS Trials with Complex Intercurrent Events

✅ What Pharma Can Learn from Data Science Outside the Industry

These sessions will be presented by Ben Kaspar, Stephine Keeton, Kris Wenzel, Ian Lees and Veera Thota in an effort to explore how stronger collaboration between regulatory and programming teams improves submission readiness and how lessons from data science outside pharma can expand analytical thinking in clinical development.

View the agenda to plan your day: https://hubs.li/Q046Mp180

Request a meeting or visit the MMS booth onsite: https://hubs.li/Q046MlRW0

There are just 2 weeks left until we dive deep into early oncology data interpretation! With experts speaking from PAQ T...
03/12/2026

There are just 2 weeks left until we dive deep into early oncology data interpretation! With experts speaking from PAQ Therapeutics, Friends of Cancer Research, and MMS, this session will explore how sponsors can move beyond surface-level outputs and build stronger clinical narratives through disciplined statistical thinking and cross-functional alignment.

Early oncology programs demand clarity around endpoints, interim reads, and totality of evidence. The discussion will focus on how thoughtful interpretation shapes regulatory conversations long before submission.

If you are working in oncology development and want sharper insight into how data drives decisions, REGISTER NOW: https://hubs.li/Q046vSm50

03/11/2026

Twenty years ago, MMS began with a clear belief that data makes the difference and quality should anchor every decision.

Today, we celebrate 20 years of supporting sponsors across regulatory affairs, biometrics, safety, medical writing, and much more. What started as a focused vision has grown into a global team trusted with some of the most complex programs, expedited pathways, and high-stakes submissions globally.

To our colleagues, clients, and partners around the world, thank you for being part of the journey! The next chapter is already in motion.

What does global submission planning really require? Alignment.Our latest blog, “Behind the Scenes of Global Regulatory ...
03/10/2026

What does global submission planning really require? Alignment.

Our latest blog, “Behind the Scenes of Global Regulatory Submission Planning is a Symphony of Collaboration,” explores how regulatory, biometrics, safety, medical writing, and publishing teams work in lockstep to prepare high-quality submissions across regions.

Strong submissions are shaped early through coordinated endpoint strategy, integrated statistical planning, and clear communication across functions. If you are preparing for a global filing, this piece offers a practical look at what it takes for the most seamless submission.

Read more here: https://hubs.li/Q0467TG-0

We’re proud to share that two MMS leaders will be speaking at ACDM 2026 this year in Berlin! 1️⃣ On March 16, Doreen Van...
03/09/2026

We’re proud to share that two MMS leaders will be speaking at ACDM 2026 this year in Berlin!

1️⃣ On March 16, Doreen Van Huyssteen will present “Risk Based Data Management Success Factors and Associated Risks.,” and her session will explore how RBQM continues to shift data oversight from uniform review models to more targeted, risk-informed approaches, and what organizations must consider to implement it effectively.

2️⃣Later that day, Minya Engelbrecht will lead a session on “Clinical Data Management Soft Skill Utilization; Translating Neuro-Linguistic Programming into Higher Customer Satisfaction,” and her talk will examine how communication, mindset, and behavioral insight influence sponsor relationships and operational outcomes.

ACDM 2026 continues to bring together leaders shaping the future of clinical data management, and we look forward to the discussions ahead! If you’re attending, message our team to connect onsite: https://hubs.li/Q045_TJ60

View the entire agenda here: https://hubs.li/Q045_Swp0

MMS will be attending the RIC Annual Meeting 2026 next week in Arlington, Virginia.Hosted by the REMS Industry Consortiu...
03/06/2026

MMS will be attending the RIC Annual Meeting 2026 next week in Arlington, Virginia.
Hosted by the REMS Industry Consortium, the RIC Annual Meeting brings together REMS professionals, regulators, sponsors, and industry partners to collaborate on best practices, standardisation, and innovation across REMS programmes all with a shared focus on advancing patient safety and appropriate access to medicines.

Our team will be on site on 11–12 March at the Westin Arlington, taking part in discussions around REMS modernisation, regulatory expectations, and the evolving risk management landscape.

If you’re attending RIC 2026, feel free to connect with:
Somya Dunn, Senior Medical Director, Safety Risk Management
Mark Bernath, Director, Business Development
Christine Manley, Director, REMS & Pharmacovigilance

We’re looking forward to engaging conversations and connecting with peers across the REMS community!

Address

6880 Commerce Boulevard
Canton, MI
48187

Telephone

+17342450310

Website

Alerts

Be the first to know and let us send you an email when MMS posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to MMS:

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Our Story

MMS is an award-winning, data-focused CRO that supports the pharmaceutical and biotech industries with a proven, scientific approach to complex trial data and regulatory submission challenges. Strong industry experience and a data-driven approach to drug development make MMS a valuable CRO partner, creating compelling submissions that meet rigorous regulatory standards. With a global footprint across four continents, MMS maintains a 97 percent customer satisfaction rating and was named as the Best Global Biotech CRO in the 2018 International Life Sciences Awards.